Urogen Pharma Ltd
NASDAQ:URGN
Urogen Pharma Ltd
NASDAQ:URGN
Price:
14.4 USD
4.2%
Market Closed
Updated:
May 2, 2024
Urogen Pharma Ltd
Cash from Financing Activities
|
Urogen Pharma Ltd
Cash from Financing Activities Peer Comparison
Comparables:
CLGN
KMDA
B
BLRX
ENTX
B
BONS
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Cash from Financing Activities
$116.9m
|
CAGR 3-Years
92%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Cash from Financing Activities
$1.1m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Cash from Financing Activities
$22.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-7%
|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Cash from Financing Activities
$15.1m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
3%
|
CAGR 10-Years
0%
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Cash from Financing Activities
$6m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Cash from Financing Activities
-₪1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Urogen Pharma Ltd's Cash from Financing Activities?
Cash from Financing Activities
116.9m
USD
116.9m
USD
Based on the financial report for Dec 31, 2023, Urogen Pharma Ltd's Cash from Financing Activities amounts to 116.9m USD.
What is Urogen Pharma Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
12%
12%
Over the last year, the Cash from Financing Activities growth was 20%. The average annual Cash from Financing Activities growth rates for Urogen Pharma Ltd have been 92% over the past three years , 12% over the past five years .
You don't have any saved screeners yet
